After the aborted Alcon deal, LENSAR shows its independence works—83% of revenue is now recurring, and a tariff refund gives margins a kick.
LNSR · Earnings Call · 2026-08-13
Back on the Front Foot
LENSAR, the small-cap ophthalmic laser maker, has put the uncertainty of a terminated Alcon merger behind it. In Q2 2026, the company reported total revenue of $16.5 million, up 18% year-over-year, with recurring revenue business growing 20% to $13.7 million. More tellingly, procedure revenue jumped 23% to $10.2 million, and the company achieved its strongest adjusted EBITDA ever.
We delivered 18% total revenue growth with Q2 revenue of $16.5 million, 20% recurring revenue growth of $13.7 million and 23% procedure revenue growth to $10.2 million, while also achieving our strongest adjusted EBITDA performance to date.
That performance isn't just a bounce; it's evidence that the strategic pivot to independence is working. The company placed 10 ALLY systems in the quarter, bringing the installed base to ~215, and U.S. procedure market share rose to 24.1% from 23.4% in Q1.
This momentum isn't accidental. Management has consciously focused on building a durable base of ALLY System users. As Nick Curtis explained, “The long-term value of our business isn't simply measured by the number of systems we place in any given quarter. It's measured by what happens after those systems are installed.” The results confirm this: procedures performed on the installed base grew 31% above the national average, and recurring revenue now makes up 83% of total revenue. This shift to a subscription-like model is exactly what Wall Street likes to see, especially from a small-cap with a history of volatility.
The Tariff Tailwind
One notable line in the quarter was a tariff refund of $1.1 million recorded in cost of goods sold. That benefit lifted gross margin to 59% on a GAAP basis; without it, the margin was 52%, still a solid improvement from 50% a year ago. The refund is directly in line with a broader global wave of IEEPA tariff refunds that many companies reported in the same period. As CFO Michael Rossi noted, “We recorded a $1.1 million benefit in cost of goods sold related to a tariff refund in Q2. Without this benefit, gross margin was 52%.” This one-time boost is unlikely to repeat, but it does provide a cushion as the company ramps up its commercial investments.
The tariff story isn't just a company-specific nuance. The global context shows that 'tariff refund' was the top keyword in the market for Q2 2026, with many companies citing favorable refunds. For LENSAR, it's a welcome kicker, but the core strength lies in the recurring revenue engine, which is less exposed to trade policy swings.
Investing for the Long Haul
Management is careful not to overpromise. They noted that Q3 is seasonally the weakest for cataract procedures due to holidays and vacations. They also flagged that operating expenses will “trend modestly higher” as they rebuild the commercial organization and invest in Europe, where they'll take a direct presence at the ESCRS meeting for the first time. This is a deliberate restart after the merger freeze. Nick Curtis acknowledged the rebuilding is still underway: “It's going to take us a few quarters there to fully—the transaction stopped much of the activity.” The prior quarter's commentary reinforces this; Tom Staab had said, “the U.S. business is still doing pretty well. But outside the United States, you're kind of like a flat line up until the activity that Nick just mentioned.” Now, distributor orders are returning, and the company expects to ship systems OUS again.
The stock has already responded, rallying 52% over the last 90 days, with a 44% jump in the last nine days—likely a direct reaction to the strong earnings. The recent gross margin trajectory shows that despite a dip in Q1, the company is now operating at a structurally higher level thanks to the recurring mix. However, with a market cap under $100 million, LENSAR remains a high-risk, high-upside story. The tariff refund won't recur, but the shift toward recurring revenue and the rebuilding of the international pipeline provide a credible path to sustainable growth.
In short, LENSAR has turned the page. The numbers are improving, the model is strengthening, and the company is finally moving forward with a clear strategy. The key will be sustaining this momentum through the seasonally weak third quarter and converting the distributor pipeline into placements. “We've put the uncertainty of the past year behind us, and we're fully focused on executing our strategy, and we see evidence of this execution in our top line growth.” — Nicholas Curtis, CEO · 2026-08-13